Proto-Oncogene Proteins c-mdm2
"Proto-Oncogene Proteins c-mdm2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An E3 UBIQUITIN LIGASE that interacts with and inhibits TUMOR SUPPRESSOR PROTEIN P53. Its ability to ubiquitinate p53 is regulated by TUMOR SUPPRESSOR PROTEIN P14ARF.
| Descriptor ID |
D051736
|
| MeSH Number(s) |
D08.811.464.938.750.562 D12.776.624.664.700.185 D12.776.660.764
|
| Concept/Terms |
Proto-Oncogene Proteins c-mdm2- Proto-Oncogene Proteins c-mdm2
- Proto Oncogene Proteins c mdm2
- c-mdm2, Proto-Oncogene Proteins
- Mdm2 Protein
- Double Minute 2 Protein
- c-mdm2 Proto-Oncogene Protein
- Proto-Oncogene Protein, c-mdm2
- c mdm2 Proto Oncogene Protein
- Murine Double Minute 2 Protein
- Mdm-2 Protein
- Mdm 2 Protein
- MDMX Protein
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-mdm2".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-mdm2".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-mdm2" by people in this website by year, and whether "Proto-Oncogene Proteins c-mdm2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 5 | 5 | 10 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-mdm2" by people in Profiles.
-
MDM2-Mediated Ubiquitination of Angiotensin-Converting Enzyme 2 Contributes to the Development of Pulmonary Arterial Hypertension. Circulation. 2020 09 22; 142(12):1190-1204.
-
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Invest New Drugs. 2020 06; 38(3):831-843.
-
Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment. Biomed Pharmacother. 2019 Jan; 109:484-492.
-
Influenza A viruses alter the stability and antiviral contribution of host E3-ubiquitin ligase Mdm2 during the time-course of infection. Sci Rep. 2018 02 27; 8(1):3746.
-
LRRK2 interacts with ATM and regulates Mdm2-p53 cell proliferation axis in response to genotoxic stress. Hum Mol Genet. 2017 11 15; 26(22):4494-4505.
-
MDM4 amplification in a case of de-differentiated liposarcoma and in-silico data supporting an oncogenic event alternative to MDM2 amplification in a subset of cases. Histopathology. 2017 12; 71(6):1019-1023.
-
Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway. Prog Mol Biol Transl Sci. 2017; 151:195-216.
-
GATA4 is highly expressed in childhood acute lymphoblastic leukemia, promotes cell proliferation and inhibits apoptosis by activating BCL2 and MDM2. Mol Med Rep. 2017 Nov; 16(5):6290-6298.
-
Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest. PLoS One. 2017; 12(7):e0181081.
-
TP53 in adult acute lymphoblastic leukemia. Leuk Lymphoma. 2018 04; 59(4):778-789.